所以霍普金斯大學的疫苗專家Anna Durbin教授認為:"The Ad5 concerns me just because a lot of people have immunity,";“I'm not sure what their strategy is ... maybe it won't have 70% efficacy. It might have 40% efficacy, and that's better than nothing, until something else comes along."
回複 'house6688' 的評論 : 謝謝,需要問臨床試驗專家的意見,他們能夠這樣做嗎?在臨床試驗中根據不同人群的Ad5抗體打安慰劑組與疫苗組?隻在天朝這樣做,似乎在巴基斯坦和俄羅斯沒有這樣做?“In contrast, Ad5 seroprevalence may only be around 30% in western countries, he added. Convidicea has emergency authorisation in China and is in three ex-China trials that together are recruiting in Canada, Latin America, Pakistan and Russia. CanSino’s China-based trials divided patients according to their pre-existing Ad5 antibodies, said Richard Webby, PhD, director, WHO Collaborating Centre for Studies on the Ecology of Influenza in Animals and Birds, Memphis, Tennessee. Yet, establishing such a screening system in practice adds a logistical issue, particularly at the large scale needed, he added.”
house6688 發表評論於
https://www.clinicaltrialsarena.com/comment/adenovirus-vectored-covid-19-vaccines-efficacy-during-a-potential-revaccination/
“CanSino’s China-based trials divided patients according to their pre-existing Ad5 antibodies, said Richard Webby, PhD, director”
雅美之途 發表評論於
回複 'cng' 的評論 : 謝謝分享。J&J在南非的有效率僅為57%,是否完全對突變株無效沒有定論,預測至少是減弱了,因為它對美國的保護力是72%。但是這也可以從腺病毒Ad26在不同國家的抗體陽性率看出。在FDA申報時,針對強生疫苗使用的Ad26載體的抗體在各國的分布分別是: Brazil (33%), South Africa (69%), US (< 2%) 。https://www.google.com/amp/s/www.wsj.com/amp/articles/south-africa-rolls-out-j-j-covid-19-vaccine-to-healthcare-workers-11613564630
京華人 發表評論於
方舟子早已經把陳“將軍”歸類為學術騙子了……
cng 發表評論於
Phase 3: similar humoral immunogenicity observed in Brazil, South Africa, US despite baseline Ad26 seropositivity.
Baseline Ad26 seropositivity: Brazil (33%), South Africa (69%), US (< 2%)
Source: Vaccines and Related Biological Products Advisory Committee February 26, 2021 Meeting Presentation - Emergency Use Authorization (EUA) Application for Ad26.COV2.S